Clinical Trial Update: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating real-world use of semaglutide for liver fibrosis associated with non-alcoholic fatty liver disease in obese patients with type 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis of the Liver
• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus in Obese

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: University of California, San Diego | Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese | Phase 2 | Status: UNKNOWN